ArticleBreast cancer research and treatment2018
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Carlo Palmieri et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.